Roche Presents New Data For Ocrevus And Fenebrutinib
Refinitiv1分未満で読めます
ROCHE HOLDING AG 
RO:
ROCHE PRESENTS NEW DATA FOR OCREVUS AND FENEBRUTINIB ACROSS BROAD PATIENT POPULATIONS AT ECTRIMS 2025
ROCHE HOLDING AG - OCREVUS SUBCUTANEOUS MAINTAINS CONSISTENT BENEFIT-RISK PROFILE
ROCHE HOLDING AG - OCREVUS REDUCES DISABILITY PROGRESSION IN ADVANCED PPMS
ROCHE HOLDING AG - FENEBRUTINIB SUPPRESSES DISEASE ACTIVITY AT 96 WEEKS
ROCHE HOLDING AG - OCREVUS DELAYS DISABILITY PROGRESSION AND IMPROVES LIMB FUNCTION
ROCHE HOLDING AG - OCREVUS REDUCES DISABILITY PROGRESSION RISK BY 30% IN PPMS
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう